Cencora (0HF3.L) Q3 2024: 0hf3 L

Next: Q4 2024

Cencora

0HF3.L

$337.94 0.27%

Exchange: LSE | Sector: Healthcare | Industry: Medical Distribution

Q3 2024

Published: Jul 31, 2024

Earnings Highlights

Revenue of $74.24B up 7.7% year-over-year
EPS of $2.42 increased by 41% from previous year
Gross margin of 2.8%
Net income of 483.46M
""We are strategically positioned to navigate the complexities of the healthcare landscape, ensuring robust distribution solutions for our partners."" - CEO

0HF3.L

Cencora

Period Q3 2024

Currency USD

Report Type Quarterly Earnings

Generated Dec 10, 2025

Executive Summary

Cencora (0HF3.L) showcased a robust performance in Q3 2024, achieving revenue of $74.24 billion, reflecting an 8.52% increase quarter-over-quarter (QoQ) and 7.72% year-over-year (YoY). Despite challenges in gross profit driven by higher costs, the company demonstrated an impressive 37.91% surge in net income, amounting to $483.46 million, supported by effective cost management and strategic market positioning. Management emphasized their commitment to expanding operations in both domestic and international pharmaceutical distribution, enhancing service capabilities, which positions them well against competitive pressures in the industry.

Key Performance Indicators

Revenue

Increasing

74.24B

QoQ: 8.52% | YoY: 7.72%

Gross Profit

Decreasing

2.09B

2.81% margin

QoQ: -7.93% | YoY: -5.62%

Operating Income

Increasing

703.37M

QoQ: -19.84% | YoY: 30.07%

Net Income

Increasing

483.46M

QoQ: 14.90% | YoY: 37.91%

EPS

Increasing

2.44

QoQ: 15.64% | YoY: 41.04%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: $74.24 billion, YoY Growth: 7.72%, QoQ Growth: 8.52%.
Gross Profit: $2.09 billion, YoY Decline: 5.62%, QoQ Decline: 7.93%.
Operating Income: $703.37 million, YoY Growth: 30.07%, QoQ Decline: 19.84%.
Net Income: $483.46 million, YoY Growth: 37.91%, QoQ Growth: 14.90%.
EPS: $2.44, YoY Growth: 41.04%, QoQ Growth: 15.64%.

These shifts indicate a strong bottom line performance despite increased operational challenges and highlight management's effective cost controls amid fluctuating revenue streams.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	74.24B	7.72%	8.52%
Gross Profit	2.09B	-5.62%	-7.93%
Operating Income	703.37M	30.07%	-19.84%
Net Income	483.46M	37.91%	14.90%
EPS	2.44	41.04%	15.64%

Key Financial Ratios

Gross Profit Margin

Weak

3.18%

Gross profit margin is below industry norms, profitability concerns

Operating Profit Margin

Weak

0.91%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

0.65%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

0.72%

Return on assets suggests inefficient capital allocation

Return on Equity

Strong

52.30%

Return on equity demonstrates excellent capital efficiency and value creation

Current Ratio

Concern

0.89

Current ratio below safe levels, potential liquidity risk

Debt to Equity

High Risk

5.11

Debt-to-equity indicates high leverage and elevated financial risk

P/E Ratio

Fair Value

23.23x

P/E ratio in line with market averages

Price to Book

High Premium

48.56x

Very high premium suggests asset-light business model or lofty expectations

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q3 2025	80,663.53	3.52	+8.7%	View
Q2 2025	75,453.67	3.68	+10.3%	View
Q1 2025	81,487.06	2.50	+12.8%	View
Q4 2024	79,050.11	0.02	+14.7%	View
Q3 2024	74,241.35	2.42	+7.7%	View

Cencora (0HF3.L) Q3 2024 Earnings Report

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More 0HF3.L Quarterly Reports

0HF3.L

0HF3.L

0HF3.L

0HF3.L

Related Financial Data

Sector Analysis: Healthcare

0HF3.L Full Profile

0HF3.L Financial Statements

Earnings Calendar